TTL Recombinant antibody

TTL Recombinant Antibody for WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human, mouse, rat

Applications

WB, ELISA

Conjugate

Unconjugated

CloneNo.

3P9

Cat no : 82763-5-RR

Synonyms

TTL, Tubulin tyrosine ligase, tubulin tyrosine ligase

---

Validation Data Gallery

• 

  WB analysis using 82763-5-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 82763-5-RR (TTL antibody) at dilution of 1:8000 incubated at room temperature for 1.5 hours.

---

Tested Applications

• Positive WB detected in: HeLa cells, SH-SY5Y cells, U2OS cells, Y79 cells, Jurkat cells, mouse brain tissue, rat brain tissue

Recommended dilution

• Western Blot (WB): WB : 1:2000-1:16000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Product Information

82763-5-RR targets TTL in WB, ELISA applications and shows reactivity with Human, mouse, rat samples.

• Tested Reactivity: Human, mouse, rat
• Host / Isotype: Rabbit / IgG
• Class: Recombinant
• Type: Antibody
• Immunogen: TTL fusion protein Ag4526
• Full Name: tubulin tyrosine ligase
• Calculated Molecular Weight: 377 aa, 43 kDa
• Observed Molecular Weight: 43 kDa
• GenBank Accession Number: BC036819
• Gene Symbol: TTL
• Gene ID (NCBI): 150465
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Tubulin-tyrosine ligase (TTL) is the enzyme responsible for the reversible addition of a tyrosine residue at the carboxyl end of alpha-tubulin. TTL forms stable complexes with tubulin and inhibit tubulin polymerization. TTL is frequently suppressed during tumor progression with resulting accumulation of detyrosinated alpha-tubulin in tumor cells. TTL suppression in human cancers is associated with increased tumor aggressiveness.